Clinical Data Merck, Eisai’s Keytruda triplet fails to improve survival in kidney cancer pharminent April 21, 2026
Clinical Data Gilead, Arcus tumble again in TIGIT, triggering 2 trial culls pharminent April 21, 2026
Regulatory Pfizer and Astellas secure FDA priority review for Padcev MIBC combo therapy pharminent April 21, 2026
Regulatory Pfizer and Astellas secure FDA priority review for Padcev MIBC combo therapy pharminent April 21, 2026
Other AACR 2026: Revolution’s next prospect, Merck’s reveal and a lung cancer battle pharminent April 20, 2026
Other S16 Ep55: OncoBytes Adaptive Learning Pathways: Personalizing Treatment Plans to Optimize Adjuvant Therapy in Early-Stage HR+/HER2- Breast Cancer pharminent April 20, 2026
Other S16 Ep53: Live Tumor Board: Squamous Cell Carcinoma of the Head & Neck – Post-CRT Decisions in the Locally Advanced Setting pharminent April 17, 2026
Commercial Revolution doubles stock offering target to $2B following pancreatic cancer win pharminent April 16, 2026
M&A / Deals Terremoto wins $108m in Series C to drive cancer and rare disease programmes pharminent April 16, 2026
Clinical Data Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study pharminent April 16, 2026
Clinical Data Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study pharminent April 16, 2026
Clinical Data S16 Ep52: Medical Crossfire: PD-L1 Inhibition in Advanced Cutaneous Squamous Cell Carcinoma — Mechanistic Rationale and Clinical Application pharminent April 15, 2026
Regulatory MSD, Daiichi Sankyo’s ifinatamab deruxtecan receives FDA priority pharminent April 14, 2026
Regulatory MSD, Daiichi Sankyo’s ifinatamab deruxtecan receives FDA priority pharminent April 14, 2026
Clinical Data Allogene data suggest ‘off-the-shelf’ CAR-T could delay relapse in lymphoma pharminent April 13, 2026
Clinical Data Allogene stock sails after CAR T clears residual lymphoma in early data cut pharminent April 13, 2026
Clinical Data Revolution rises 40% as pancreatic cancer drug doubles survival pharminent April 13, 2026
Regulatory IDEAYA and Servier’s eye cancer drug heads to FDA after delivering ‘best in class’ efficacy pharminent April 13, 2026
Regulatory FDA issues complete response letter to Replimune’s RP1 for melanoma pharminent April 13, 2026
Regulatory FDA issues complete response letter to Replimune’s RP1 for melanoma pharminent April 13, 2026
M&A / Deals Oricell closes a ‘pre-IPO’ megaround to aim CAR-T at solid tumors pharminent April 10, 2026
M&A / Deals Roche and C4 Therapeutics to advance degrader-antibody conjugates research pharminent April 10, 2026
Other Precision Medicine in Early Oncology Trials: Biomarkers as Strategic Drivers pharminent April 10, 2026
